GLP-1 Receptor Agonist Market to Reach USD19,253.8 Million, at 6.1%CAGR by 2028 | Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S

GLP-1 Receptor Agonist Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide GLP-1 Receptor Agonist industry with an attention on the Global market. The report gives key insights available status of the GLP-1 Receptor Agonist producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2021-2028 worldwide GLP-1 Receptor Agonist Market covering extremely significant parameters.

Request Sample Report + Related Graphs & Charts @:
https://www.coherentmarketinsights.com/insight/request-sample/4632

Key Players in This Report Include Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, PegBio Co., Ltd., AstraZeneca, Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm. Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.

Brief Summary of GLP-1 Receptor Agonist:

GLP-1 receptor (Glucagon like peptide-1 receptor) is a receptor protein found in the neurons of the brain and the beta cells of pancreas. GLP-1 receptor is involved in regulating the process of insulin secretion in the body. GLP-1 and glucagon are the natural endogenous agonists of GLP-1 receptor. An agonist is a chemical entity which induces a biological response by binding to a receptor and activating it. Some of the other agonists of GLP-1 receptor include exenatide, lixisenatide, albiglutide, liraglutide, dulaglutide, and semaglutide. GLP-1 receptor agonists are commonly used for the treatment of diabetes and obesity. When an agonist binds to the GLP-1 receptor the receptor becomes activated and results in stimulation of adenylyl cyclase pathway.

According to International Diabetes Federation (IDF) Diabetes Atlas: 2017, the number of people with diabetes aged between 20 to 79 years in South and Central America region in 2017 was 26 million. This number is estimated to increase 62% in 2045, accounting for 42 million.

Moreover, according to an article published by the Nature scientific journal in May 2021, the combined prevalence of obesity in Australia was estimated to be 26% in 2019 and it is estimated that it will reach 35% by 2025.

For instance, in April 2020, Novo Nordisk A/S, a Denmark-based pharmaceutical company, received marketing authorization approval from European Medicines Agency (EMA) for its drug, Rybelsus (semaglutide) which is an oral GLP-1 receptor agonist indicated for the treatment of Type-2 diabetic people.

Moreover, in July 2020, 9 Meters Biopharma, Inc., a U.S.-based clinical-stage rare gastroenterology company, announced that the company had initiated Phase 1b/2a clinical trial to assess the efficacy and safety of its drug candidate NM-002, a glucagon-like peptide-1 (GLP-1) receptor agonist in adults with short bowel syndrome (SBS). Short Bowel Syndrome is a rare gastrointestinal disease caused by a significant shortening of the gastrointestinal tract, resulting in impairment of nutrient absorption. NM-002 is an injectable designed to treat gastric motility in short bowel syndrome patients by slowing emptying time of stomach’s digestive juices.

The Global GLP-1 Receptor Agonist Market segments and Market Data Break Down are illuminated below:

By Drug Class:
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide

By Route of Administration:
Parenteral
Oral

By Application:
Type 2 Diabetes Mellitus
Obesity
Liver Cirrhosis
Non-alcoholic Steatohepatitis
Others (Others include Cardiovascular Disease and Type-1 Diabetes)

By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

This research report represents a 360-degree overview of the competitive landscape of the Global GLP-1 Receptor Agonist Market. Furthermore, it offers massive data relating to recent trends, technological, advancements, tools, and methodologies. The research report analyzes the Global GLP-1 Receptor Agonist Market in a detailed and concise manner for better insights into the businesses.

Regions Covered in the GLP-1 Receptor Agonist Market:

The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)
North America (United States, Mexico & Canada)
South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)
Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)
Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).

Request for customization in Report @ https://www.coherentmarketinsights.com/insight/request-customization/4632

The research study has taken the help of graphical presentation techniques such as infographics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global GLP-1 Receptor Agonist Market.

The detailed elaboration of the Global GLP-1 Receptor Agonist Market has been provided by applying industry analysis techniques such as SWOT and Porter’s five-technique. Collectively, this research report offers a reliable evaluation of the global market to present the overall framework of businesses.

Attractions of the GLP-1 Receptor Agonist Market Report:

• The report provides granular level information about the market size, regional market share, historic market (2016-2020) and forecast (2021-2028)

• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies

• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market

• The report tracks recent innovations, key developments and start-up’s details that are actively working in the market

• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Get Discount On The Purchase Of This Report @: https://www.coherentmarketinsights.com/promo/buynow/4632

GLP-1 Receptor Agonist Market research provides answers to the following key questions:

• What is the expected growth rate of the GLP-1 Receptor Agonist Market?

• What will be the GLP-1 Receptor Agonist Market size for the forecast period, 2021–2028?

• What are the main driving forces responsible for changing the GLP-1 Receptor Agonist Market trajectory?

• Who are the big suppliers that dominate the GLP-1 Receptor Agonist Market across different regions? Which are their wins to stay ahead in the competition?

• What are the GLP-1 Receptor Agonist Market trends business owners can rely upon in the coming years?

• What are the threats and challenges expected to restrict the progress of the GLP-1 Receptor Agonist Market across different countries?

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Middle East, Africa, Europe or LATAM, Southeast Asia.

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights :

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.